Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Moving toward disease modification in polycythemia vera

Jan Philipp Bewersdorf, Joan How, Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, John Mascarenhas, Raajit K. Rampal

Blood (2023) 142 (22): 1859–1870.

https://doi.org/10.1182/blood.2023021503

Published: 2023

Journal Articles

TP53 mutations and Their Impact on Survival in Patients with Myeloproliferative Neoplasms

Benjamin Rolles, Cilomar Martins De Oliveira Filho, Julia Keating, Marlise R. Luskin, Daniel J. DeAngelo, Coleman Lindsley, Annette S. Kim, Jessica Hem, Chulwoo J. Kim, Lachelle D. Weeks, Mohammed Wazir, Joan How, Anna E. Marneth, Yiwen Liu, Martin J. Aryee, Harrison K. Tsai, Maximilian Stahl, Ann Mullally

Blood (2023) 142 (Supplement 1): 3160.

https://doi.org/10.1182/blood-2023-185024

Published: 2023

Journal Articles

Myeloid Neoplasia in Patients with Hereditary Hemoglobinopathies and Hemolytic Anemias (HHAs)

Miriam A. Osei, Lauren E. Merz, Kelly S. Chien, Danielle E. Hammond, Coleman Lindsley, Marlise R. Luskin, Maximilian Stahl, Joan How, Mohammed Wazir, Anna E. Marneth, Shai Shimony, Ann Mullally, Daniel J. DeAngelo, Guillermo Garcia-Manero, Maureen Okam Achebe, Benjamin L. Ebert, Lachelle D. Weeks

Blood (2023) 142 (Supplement 1): 2427.

https://doi.org/10.1182/blood-2023-172992

Published: 2023

Journal Articles

Mutations in the RNA Splicing Factors U2AF1 and SRSF2 are Context-Dependent in Myeloproliferative Neoplasms

Swarna Bale, Chulwoo J. Kim, Joan How, Mohammed Wazir, Lachelle D. Weeks, Maximilian Stahl, Marlise R. Luskin, Daniel J. DeAngelo, Coleman Lindsley, Annette S. Kim, Ann Mullally, Anna E. Marneth

Blood (2023) 142 (Supplement 1): 1788.

https://doi.org/10.1182/blood-2023-178657

Published: 2023

Journal Articles

Cardiovascular Risk Factors Are Common in Myeloproliferative Neoplasms and Portend Worse Survival and Thrombotic Outcomes

Joan How, Orly Leiva, Anna E. Marneth, Baransel Kamaz, Chulwoo J. Kim, Lachelle D. Weeks, Mohammed Wazir, Maximilian Stahl, Daniel J. DeAngelo, R. Coleman Lindsley, Marlise R. Luskin, Gabriela S. Hobbs

Blood (2023) 142 (Supplement 1): 4568.

https://doi.org/10.1182/blood-2023-179324

Published: 2023

Journal Articles

Myelofibrosis Is Associated with Poor Cardiovascular Outcomes after Heart Failure Hospitalization

Orly Leiva, Jose Alvarez-Cardona, Andrew M. Brunner, Chi-Joan How, Gabriela S. Hobbs

Blood (2023) 142 (Supplement 1): 3203.

https://doi.org/10.1182/blood-2023-173589

Published: 2023

Journal Articles

Unlike TET2 and ASXL1 , Co-Occurring DNMT3A Mutations Are Not Associated with Increased Age in JAK2 -Mutant Myeloproliferative Neoplasms (MPNs)

Joan How, Anna E. Marneth, Baransel Kamaz, Chulwoo J. Kim, Donna S. Neuberg, Siyang Ren, Mohammed Wazir, Lachelle D. Weeks, Maximilian Stahl, Daniel J. DeAngelo, R. Coleman Lindsley, Marlise R. Luskin, Sahand Hormoz, Ann Mullally

Blood (2023) 142 (Supplement 1): 4521.

https://doi.org/10.1182/blood-2023-179407

Published: 2023

Journal Articles

No Increased Incidence of Bleeding in Essential Thrombocythemia Patients with Extreme Thrombocytosis

Rathnam K. Venkat, Robert A. Redd, Martin J. Aryee, Anna E. Marneth, Baransel Kamaz, Chulwoo J. Kim, Mohammed Wazir, Lachelle D. Weeks, Maximilian Stahl, Daniel J. DeAngelo, Coleman Lindsley, Marlise R. Luskin, Gabriela S. Hobbs, Joan How

Blood (2023) 142 (Supplement 1): 1839.

https://doi.org/10.1182/blood-2023-187530

Published: 2023

Journal Articles

Myeloproliferative Neoplasms Are Associated with Increased Risk of Major Adverse Limb Events Among Patients Hospitalized for Peripheral Arterial Disease

Orly Leiva, Andrew M. Brunner, Joan How, Gabriela S. Hobbs, Jeffrey S Berger

Blood (2023) 142 (Supplement 1): 4570.

https://doi.org/10.1182/blood-2023-180783

Published: 2023

Journal Articles

Biology and therapeutic targeting of molecular mechanisms in MPNs

Joan How, Jacqueline S. Garcia, Ann Mullally

Blood (2023) 141 (16): 1922–1933.

https://doi.org/10.1182/blood.2022017416

Published: 2023

Journal Articles

Trends in All-Cause and Cardiovascular Mortality Among Patients with Myeloproliferative Neoplasms: A Surveillance, Epidemiology, and End Results Database Analysis

Orly Leiva, Chi-Joan How, Andrew M. Brunner, Gabriela S. Hobbs

Blood (2022) 140 (Supplement 1): 6808–6809.

https://doi.org/10.1182/blood-2022-170607

Published: 2022

Journal Articles

Real-World Experience of Ropeginterferon in Myeloproliferative Neoplasm Patients

Chi-Joan How, Gabriela S. Hobbs

Blood (2022) 140 (Supplement 1): 12284–12285.

https://doi.org/10.1182/blood-2022-157076

Published: 2022

Journal Articles

Immunologic Responses to Sars-Cov-2 Vaccination in Myeloproliferative Neoplasm Patients: Durability, Booster Responses, and Associations with Infections

Joan How, Kathleen M.E. Gallagher, Yiwen Liu, Katelin Katsis, Eva Elder, Donna S. Neuberg, Patrick M. Reeves, Marcela V. Maus, Gabriela S. Hobbs

Blood (2022) 140 (Supplement 1): 6852–6853.

https://doi.org/10.1182/blood-2022-157628

Published: 2022

Journal Articles

Mutant Srsf2 Diminishes Jak2 V617F -Induced Erythrocytosis in Mice and Is Associated with Lower Hemoglobin in Patients with Chronic Phase JAK2 -Mutant MPN

Anna E Marneth, Jonas S. Jutzi, Chulwoo J. Kim, Charles Laurore, Anastasia Tishena, Frederike Kramer, Azucena V. Rocha, Mohammed Wazir, Lachelle D. Weeks, Joan How, Maximilian F. Stahl, Marlise R. Luskin, R. Coleman Lindsley, Olga Pozdnyakova, Timothy A. Graubert, Ann Mullally

Blood (2022) 140 (Supplement 1): 1089–1090.

https://doi.org/10.1182/blood-2022-158823

Published: 2022

Journal Articles

Antibody and T-Cell Responses to COVID-19 Vaccination in Myeloproliferative Neoplasm Patients

Joan How, Kathleen M.E. Gallagher, Yiwen Liu, Ashley DeMato, Katelin Katsis, Rebecca Larson, Mark B. Leick, Donna S. Neuberg, Marcela V. Maus, Gabriela Hobbs

Blood (2021) 138 (Supplement 1): 316.

https://doi.org/10.1182/blood-2021-145657

Published: 2021

Journal Articles

High Incidence of Bleeding Found with Direct Oral Anticoagulant Use in Myeloproliferative Neoplasm Patients

Chi-Joan How, Charlotte McIlwaine Story, Siyang Ren, Donna S. Neuberg, Rachel P. Rosovsky, Gabriela Hobbs, Jean M. Connors

Blood (2021) 138 (Supplement 1): 3632.

https://doi.org/10.1182/blood-2021-148941

Published: 2021

Journal Articles

Immune Profiling of Responses to Influenza Vaccination in Patients with Myeloproliferative Neoplasms

Joan How, Petra Bachanova, Maia Pavlovic, Patrick M. Reeves, Gabriela Hobbs

Blood (2021) 138 (Supplement 1): 3631.

https://doi.org/10.1182/blood-2021-153327

Published: 2021

Journal Articles

Evaluation of a Pan-Lysyl Oxidase Inhibitor, Pxs-5505, in Myelofibrosis: A Phase I, Randomized, Placebo Controlled Double Blind Study in Healthy Adults

Joan How, MD, Yiwen Liu, Jennifer Lombardi Story, Donna S. Neuberg, ScD, Katya Ravid, PhD DSc, Wolfgang Jarolimek, Brett Charlton, Gabriela S. Hobbs, MD

Blood (2020) 136 (Supplement 1): 16.

https://doi.org/10.1182/blood-2020-139223

Published: 2020

Journal Articles

A Phase 1 Trial of Regorafenib in Advanced Myeloid Malignancies

Chi-Joan How, MD, Siyang Ren, Jennifer Lombardi Story, Meghan Bergeron, NP, Julia E. Foster, NP, Philip C. Amrein, MD, Andrew M. Brunner, Amir T. Fathi, Hanno R. Hock, MD PhD, Jenna A. Moran, NP, Rupa Narayan, Donna S. Neuberg, ScD, Aura Y. Ramos, RN, Tina T. Som, RN, Megan Vartanian, RN, Yi-Bin Chen, MD, Gabriela S. Hobbs, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-140278

Published: 2020

Journal Articles

Mutant calreticulin in myeloproliferative neoplasms

Joan How, Gabriela S. Hobbs, Ann Mullally

Blood (2019) 134 (25): 2242–2248.

https://doi.org/10.1182/blood.2019000622

Published: 2019

NARROW

Moving toward disease modification in polycythemia vera

TP53 mutations and Their Impact on Survival in Patients with Myeloproliferative Neoplasms

Myeloid Neoplasia in Patients with Hereditary Hemoglobinopathies and Hemolytic Anemias (HHAs)

Mutations in the RNA Splicing Factors U2AF1 and SRSF2 are Context-Dependent in Myeloproliferative Neoplasms

Cardiovascular Risk Factors Are Common in Myeloproliferative Neoplasms and Portend Worse Survival and Thrombotic Outcomes

Myelofibrosis Is Associated with Poor Cardiovascular Outcomes after Heart Failure Hospitalization

Unlike TET2 and ASXL1 , Co-Occurring DNMT3A Mutations Are Not Associated with Increased Age in JAK2 -Mutant Myeloproliferative Neoplasms (MPNs)

No Increased Incidence of Bleeding in Essential Thrombocythemia Patients with Extreme Thrombocytosis

Myeloproliferative Neoplasms Are Associated with Increased Risk of Major Adverse Limb Events Among Patients Hospitalized for Peripheral Arterial Disease

Biology and therapeutic targeting of molecular mechanisms in MPNs

Trends in All-Cause and Cardiovascular Mortality Among Patients with Myeloproliferative Neoplasms: A Surveillance, Epidemiology, and End Results Database Analysis

Real-World Experience of Ropeginterferon in Myeloproliferative Neoplasm Patients

Immunologic Responses to Sars-Cov-2 Vaccination in Myeloproliferative Neoplasm Patients: Durability, Booster Responses, and Associations with Infections

Mutant Srsf2 Diminishes Jak2 V617F -Induced Erythrocytosis in Mice and Is Associated with Lower Hemoglobin in Patients with Chronic Phase JAK2 -Mutant MPN

Antibody and T-Cell Responses to COVID-19 Vaccination in Myeloproliferative Neoplasm Patients

High Incidence of Bleeding Found with Direct Oral Anticoagulant Use in Myeloproliferative Neoplasm Patients

Immune Profiling of Responses to Influenza Vaccination in Patients with Myeloproliferative Neoplasms

Evaluation of a Pan-Lysyl Oxidase Inhibitor, Pxs-5505, in Myelofibrosis: A Phase I, Randomized, Placebo Controlled Double Blind Study in Healthy Adults

A Phase 1 Trial of Regorafenib in Advanced Myeloid Malignancies

Mutant calreticulin in myeloproliferative neoplasms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only